BridgeBio Pharma (BBIO) EBT Margin (2019 - 2026)

BridgeBio Pharma has disclosed EBT Margin across 8 years of filings, most recently posting 57.91% for Q1 2026.

• EBT Margin for Q1 2026 came in at 57.91%, up 4249.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 116.48% (up 37258.0% YoY), and the FY2025 annual result was 145.89%, up 9844.0% from the prior year.
• EBT Margin came in at 57.91% for Q1 2026 at BridgeBio Pharma, up from 126.32% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 9.02% in Q1 2024 to a low of 43350.3% in Q3 2022.
• The 5-year median for EBT Margin is 4258.25% (2023), against an average of 6485.5%.
• Across the five-year window, EBT Margin slumped 3651019 bps in 2022 and soared 3909205 bps in 2023, its largest moves.
• BridgeBio Pharma's EBT Margin stood at 7760.96% in 2022, then sank by 42 bps to 11008.94% in 2023, then soared by 59 bps to 4526.28% in 2024, then soared by 97 bps to 126.32% in 2025, then surged by 54 bps to 57.91% in 2026.
• The last three EBT Margin figures came in at 57.91% (Q1 2026), 126.32% (Q4 2025), and 154.5% (Q3 2025), per Business Quant data.